Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) EVP Ourania Tatsis Sells 530 Shares

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Get Free Report) EVP Ourania Tatsis sold 530 shares of Vertex Pharmaceuticals stock in a transaction on Thursday, February 27th. The stock was sold at an average price of $475.34, for a total transaction of $251,930.20. Following the sale, the executive vice president now directly owns 58,539 shares of the company's stock, valued at $27,825,928.26. This represents a 0.90 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Ourania Tatsis also recently made the following trade(s):

• On Tuesday, February 18th, Ourania Tatsis sold 244 shares of Vertex Pharmaceuticals stock. The stock was sold at an average price of $455.06, for a total transaction of $111,034.64.
• On Tuesday, February 11th, Ourania Tatsis sold 310 shares of Vertex Pharmaceuticals stock. The stock was sold at an average price of $459.83, for a total transaction of $142,547.30.

Vertex Pharmaceuticals Stock Performance

NASDAQ VRTX traded up $3.72 during trading hours on Tuesday, hitting $487.03. 713,379 shares of the company's stock traded hands, compared to its average volume of 1,491,733. Vertex Pharmaceuticals Incorporated has a 52 week low of $377.85 and a 52 week high of $519.88. The firm has a market capitalization of $125.06 billion, a P/E ratio of -221.51, a P/E/G ratio of 2.11 and a beta of 0.41. The company has a current ratio of 2.69, a quick ratio of 2.35 and a debt-to-equity ratio of 0.01. The business's fifty day moving average price is $441.95 and its two-hundred day moving average price is $461.06.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last issued its quarterly earnings data on Monday, February 10th. The pharmaceutical company reported $3.54 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $3.99 by ($0.45). Vertex Pharmaceuticals had a negative net margin of 4.86% and a negative return on equity of 2.02%. Equities research analysts predict that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current year.

Hedge Funds Weigh In On Vertex Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Highline Wealth Partners LLC purchased a new stake in Vertex Pharmaceuticals in the 3rd quarter worth $27,000. Dunhill Financial LLC lifted its position in shares of Vertex Pharmaceuticals by 70.6% in the third quarter. Dunhill Financial LLC now owns 58 shares of the pharmaceutical company's stock worth $27,000 after buying an additional 24 shares in the last quarter. Brown Lisle Cummings Inc. bought a new position in Vertex Pharmaceuticals during the fourth quarter valued at approximately $30,000. Legacy Investment Solutions LLC bought a new stake in Vertex Pharmaceuticals in the 3rd quarter worth approximately $33,000. Finally, Truvestments Capital LLC purchased a new stake in Vertex Pharmaceuticals during the third quarter valued at $35,000. Institutional investors own 90.96% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms have issued reports on VRTX. Cantor Fitzgerald restated an "overweight" rating and issued a $480.00 price objective on shares of Vertex Pharmaceuticals in a research report on Tuesday, February 11th. Needham & Company LLC restated a "hold" rating on shares of Vertex Pharmaceuticals in a report on Tuesday, February 11th. UBS Group upped their price target on Vertex Pharmaceuticals from $562.00 to $586.00 and gave the stock a "buy" rating in a research note on Tuesday, November 5th. William Blair reiterated an "outperform" rating on shares of Vertex Pharmaceuticals in a research note on Friday, January 31st. Finally, BMO Capital Markets set a $545.00 target price on Vertex Pharmaceuticals in a report on Friday, January 31st. Eleven investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Vertex Pharmaceuticals presently has an average rating of "Moderate Buy" and an average target price of $506.70.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.